KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
8.75
+0.45 (5.42%)
Jan 21, 2025, 4:00 PM EST - Market closed
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$1,042,580
Market Cap
432.41M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
KALV News
- 22 hours ago - KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema - Business Wire
- 13 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha
- 5 weeks ago - KalVista Appoints Jeb Ledell as Chief Operating Officer - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - Business Wire
- 2 months ago - KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire
- 2 months ago - KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire